RhumbLine Advisers
INDV icon

RhumbLine Advisers’s Indivior Pharmaceuticals INDV Stock Holding History

RhumbLine Advisers’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5M Sell
281,329
-52,002
-16% -$1.89M 0.01% 1027
2026
Q1 		$10.2M Buy
333,331
+18,001
+6% +$594K 0.01% 1054
2025
Q4 		$11.3M Buy
315,330
+144,561
+85% +$4.41M 0.01% 1001
2025
Q3 		$4.12M Sell
170,769
-5,220
-3% -$109K ﹤0.01% 1536
2025
Q2 		$2.59M Buy
+175,989
New +$2.05M ﹤0.01% 1748

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RhumbLine Advisers's INDV Position: Q2 2026 in Review

RhumbLine Advisers reduced its Indivior Pharmaceuticals (INDV) stake by 16% in Q2 2026, selling an estimated $1.89M and leaving 281,329 shares worth $11.5M. The position accounts for 0.01% of the portfolio, ranked #1027.

RhumbLine Advisers first reported a position in INDV in Q2 2025 and has held it in 5 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • RhumbLine Advisers held 281,329 shares of Indivior Pharmaceuticals worth $11.5M as of Q2 2026.
  • RhumbLine Advisers sold 52,002 Indivior Pharmaceuticals shares in Q2 2026, an estimated $1.89M.
  • Indivior Pharmaceuticals made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1027 holding.
  • RhumbLine Advisers first reported a position in Indivior Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.